Apr 30, 2008 by Brian LawlerThe Start of a New EndoThe drugmaker marks its first quarter under new management.
Apr 30, 2008 by Brian LawlerPfizer Protects Profitable PatentThe courts uphold a key patent on its top drug.
Apr 29, 2008 by Brian LawlerSo Pharmasset, So GoodEarly data hints at a promising hepatitis C treatment.
Apr 29, 2008 by Brian LawlerMedarex Takes Another HitIts lead cancer-fighting drug suffers a regulatory delay.
Apr 29, 2008 by Brian LawlerSciele's Blue-Moon BuybackThe specialty pharmaceutical surprisingly renews its share repurchase plan.
Apr 28, 2008 by Brian LawlerBristol-Myers' Comeback ContinuesThe pharmaceutical's first quarter brings more robust results.
Apr 28, 2008 by Brian LawlerGlaxo Getting ByWeakening currency barely redeems the pharmaceutical's Q1 numbers.
Apr 28, 2008 by Brian LawlerAmgen's Anemic EarningsDrug troubles and potential label changes continue to hurt earnings.
Apr 28, 2008 by Brian LawlerImClone on the UpswingThe pharmaceutical's latest results show continuing improvement.
Apr 28, 2008 by Brian LawlerFlamel Inches ForwardNew sales data arrives for one lead drug, new data for another.
Apr 25, 2008 by Brian LawlerBiogen's Big Step ForwardThe pharmaceutical boasts better results and a rosier outlook.
Apr 25, 2008 by Brian LawlerVertex Silences the CriticsNew clinical study data bodes well for its lead drug.
Apr 24, 2008 by Brian LawlerFDA Stings Genzyme EarningsA nasty surprise hurts the drug developer's Q1 results.
Apr 23, 2008 by Brian LawlerGlaxo's Three-Quarter-Billion-Dollar GambleGlaxo adds another development stage drugmaker to its portfolio.
Apr 23, 2008 by Brian LawlerVertex Verging on Crucial NewsSoon-to-arrive study results could decide the future of lead drug telaprevir.
Apr 22, 2008 by Brian LawlerBetting on Approval for This Orphan DrugInterMune announces the release of new data for its lead drug.
Apr 22, 2008 by Brian LawlerLilly in Full Financial BloomThe pharmaceutical releases its first-quarter earnings.
Apr 21, 2008 by Brian LawlerA New Suit for VertexThe pharmaceutical's hit with a baseless, regrettably common type of lawsuit.
